Xconomy recently reported that Gossamer Bio will return to a conventional IPO approach: “With SEC Reopened, Gossamer Bio Turns Back from Alternative IPO Path.”
Back Bay managing director and M&A expert, Vasilios Kofitsas noted that “a company that decides to take the fixed-price route is likely very comfortable with its valuation—and with its disclosures to investors.
There’s certainly risk from a company perspective should you go this route and price successfully – and the SEC comes back and notices it has issues with lack of disclosures, for example.
. . . also, there is
Read about Gossamer Bio at Xconomy.com.